Metastatic prostate cancer, Prostate cancer
Conditions
Brief summary
To demonstrate that PSMA-flare seen 2-3weeks after initiation of ADT at baseline is more common in bony lesions than in prostatic lesions
Detailed description
To study if metastatic lesions with and without PSMA-flare seen in baseline behave differently in repeated 18F-PSMA-PET CT at the time of CRPC, To compare the metastatic load seen in 18F-PSMA-PET CT and FDGPET- CT at baseline (Sub-study 1), To determine the total androgen profile during the evolution of metastatic Pca by repeated total androgen measurements in every six months from diagnosis to the development of CRPC (Sub-study 2), To biopsy prostate lesions seen on 18F-PSMA PET and determine if the changes of PSMA uptake after ADT might have a histopathological correlation (Substudy 3), To investigate gut microbiome and its changes during ADT (Substudy 4)
Interventions
DRUGDEGARELIX
Sponsors
Turku University Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To demonstrate that PSMA-flare seen 2-3weeks after initiation of ADT at baseline is more common in bony lesions than in prostatic lesions | — |
Secondary
| Measure | Time frame |
|---|---|
| To study if metastatic lesions with and without PSMA-flare seen in baseline behave differently in repeated 18F-PSMA-PET CT at the time of CRPC, To compare the metastatic load seen in 18F-PSMA-PET CT and FDGPET- CT at baseline (Sub-study 1), To determine the total androgen profile during the evolution of metastatic Pca by repeated total androgen measurements in every six months from diagnosis to the development of CRPC (Sub-study 2), To biopsy prostate lesions seen on 18F-PSMA PET and determine if the changes of PSMA uptake after ADT might have a histopathological correlation (Substudy 3), To investigate gut microbiome and its changes during ADT (Substudy 4) | — |
Countries
Finland
Outcome results
None listed